latest news releases from the newsroom
Atea came out of 2003 even stronger
STOCKHOLM, Sweden, Feb. 12, 2004 (PRIMEZONE) -- Atea, the Nordic region's leading one-stop supplier of IT products and related services, has during the fourth quarter 2003 improved the result by 20 percent before taxes compared with the same period in 2002. The result for the financial year was affected by the general terms of the market, e.g. prices declining by 20 percent in average.
Haldex receives lift system order from BT Industries
STOCKHOLM, Sweden, Feb. 12, 2004 (PRIMEZONE) -- Hydraulic Systems, a division in the Haldex group, has received an order from BT Industries -- a part of Toyota Industries -- regarding lift systems for a new forklift truck series. The awarded business is worth 50 MSEK and runs over three years
Korsnas AB To Invest 650 MSEK
STOCKHOLM, Sweden, Feb. 12, 2004 (PRIMEZONE) -- Industriforvaltnings AB Kinnevik ("Kinnevik") today announced that the Board of Directors of Kinnevik and Korsnas AB have decided to invest 650 MSEK in a coating unit at the Korsnas mill.
Saab Wins Next Generation Underwater System Order Worth SEK 100 Million
LINKOPING, Sweden, Feb. 12, 2004 (PRIMEZONE) -- Saab Bofors Underwater Systems (SBUS) has received an order for a Product Definition of the next generation underwater system, TMS. TMS is short for Torpedo, Mine and Sensor. The two year SEK 100 million contract is with the Swedish Defence Materiel Administration (FMV). The FMV represents both the Swedish and the Finnish Navies.
Maxim Pharmaceuticals Announces Publication of the Discovery and Characterization of Potent Anti-Cancer Compound
STOCKHOLM, Sweden, Feb. 12, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced the publication of its manuscript entitled "Discovery, Characterization and SAR of Gambogic Acid as A Potent Apoptosis Inducer by a HTS Assay." The manuscript has been published in Bioorganic & Medicinal Chemistry (Bioorg. Med. Chem. 2004, 12, 309-317). In this paper, Maxim's scientists report the discovery of gambogic acid as a potent inducer of apoptosis (programmed cell death) using the Company's proprietary cell- and caspase-based high-throughput screening technology, and through sensitive structure-activity relationship (SAR) studies. The high potency of gambogic acid as an inducer of apoptosis, its novel mechanism of action, easy isolation and abundant supply, as well as the fact that it is amenable to chemical modification, makes it an attractive molecule for the development of a new anticancer agent.
Ahold Agrees on Restructuring of Cumulative Preferred Financing Shares
ZAANDAM, Netherlands, Feb. 12, 2004 (PRIMEZONE) -- Ahold today announced that agreement has been reached with the holders of (depository receipts of) cumulative preferred financing shares (the "Preferred Shares") on the restructuring of the Preferred Shares. The restructuring consists of (i) a limitation of their voting rights; and (ii) the possibility to convert the Preferred Shares into common shares. Item (ii) is subject to the approval of an Extraordinary General Meeting of Shareholders ("EGM") that will be held on March 3, 2004.